Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2021

View Archived Issues

MGTA-117 confers better survival in preclinical models of AML

NanoViricides reports animal safety data on broad-spectrum anti-coronavirus drug candidate NV-CoV-2

Careful with that BBB

Janssen initiates phase II portion of first-in-human trial of talquetamab

Enrollment ongoing in phase III study of LNP-023 in adults with PNH with residual anemia

mNb6-tri, a novel potent trivalent nanobody against SARS-CoV-2

Panbela provides updates regarding its development of SBP-101

Updates on clinical development of the Parkinson's disease candidate YTX-7739

Silverback Therapeutics patents TGFR-1 inhibitors

Korean investigators disclose tubulin polymerization inhibitors

Kinnate Biopharma synthesizes new CDK inhibitors

French researchers describe PD-1/PD-L1 interaction inhibitors

New bispecific antibodies presented by WuXi Biologics

Phase III trials of ziritaxestat in IPF discontinued

Celularity presents preliminary phase I data on CYNK-001 in patients with AML with MRD

FDA clears IND for phase I/II trial of PhageBank in prosthetic joint infections

New phase III study evaluates AZD-9833 with palbociclib in ER-positive HER2-negative breast cancer

Mesoblast reports phase III data on rexlemestrocel-L for chronic low back pain

Artios initiates phase I/IIa trial of ATR inhibitor ART-0380 in advanced or metastatic solid tumors

Preliminary first-in-human data for NEXI-001 shows promise for patients with relapsed AML

Early signs of Batten disease stabilization seen with gene therapy AT-GTX-502

IND cleared in U.S. for phase II study of izokibep in ankylosing spondylitis

Dependencies join mutations in precision medicine search

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...